Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DME75T
|
|||
| Drug Name |
KZR-616
|
|||
| Synonyms |
Zetomipzomib; KZR-616; 1629677-75-3; UNII-O4BT6C02M2; O4BT6C02M2; (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide; D-Erythro-3-pentulose, 4,5-anhydro-1-(1-cyclopenten-1-yl)-1,2-dideoxy-4-C-methyl-2-((N-(2-(4-morpholinyl)acetyl)-L-alanyl-(betaR)-beta-hydroxy-O-methyl-L-tyrosyl)amino)-; D-erythro-3-Pentulose, 4,5-anhydro-1-(1-cyclopenten-1-yl)-1,2-dideoxy-4-C-methyl-2-[[N-[2-(4-morpholinyl)acetyl]-L-alanyl-(betaR)-beta-hydroxy-O-methyl-L-tyrosyl]amino]-; ZETOMIPZOMIB [INN]; ZETOMIPZOMIB [USAN]; KZR616; CHEMBL4297468; SCHEMBL16118957; GTPL10409; EX-A6921; BDBM50526811; AKOS040755812; compound 12 [PMID: 30380863]; HY-114419; CS-0085023; (2S,3R)-N-((S)-3-(cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide; (2S,3R)N((S)3-(Cyclopent-1-en-1-yl)-1-((R)2-methyloxiran-2-yl)-1- oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)2-(2- morpholinoacetamido)propanamido)propenamide; 4,5-ANHYDRO-1-(1-CYCLOPENTEN-1-YL)-1,2-DIDEOXY-4-C-METHYL-2-((N-(2-(4-MORPHOLINYL)ACETYL)-L-ALANYL-(.BETA.R)-.BETA.-HYDROXY-O-METHYL-L-TYROSYL)AMINO)-D-ERYTHRO-3-PENTULOSE; 4,5-Anhydro-1-(1-cyclopenten-1-yl)-1,2-dideoxy-4-C-methyl-2-((N-(2-(4-morpholinyl)acetyl)-L-alanyl-(betaR)-beta-hydroxy-O-methyl-L-tyrosyl)amino)-D-erythro-3-pentulose
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Dermatomyositis [ICD-11: 4A41.0] | Phase 2 | [1] | |
| Polymyositis [ICD-11: 4A41.1] | Phase 2 | [1] | ||
| Company |
Kezar Life Sciences South San Francisco, CA
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C30H42N4O8
|
|||
| Canonical SMILES |
CC(C(=O)NC(C(C1=CC=C(C=C1)OC)O)C(=O)NC(CC2=CCCC2)C(=O)C3(CO3)C)NC(=O)CN4CCOCC4
|
|||
| InChI |
InChI=1S/C30H42N4O8/c1-19(31-24(35)17-34-12-14-41-15-13-34)28(38)33-25(26(36)21-8-10-22(40-3)11-9-21)29(39)32-23(16-20-6-4-5-7-20)27(37)30(2)18-42-30/h6,8-11,19,23,25-26,36H,4-5,7,12-18H2,1-3H3,(H,31,35)(H,32,39)(H,33,38)/t19-,23-,25-,26+,30+/m0/s1
|
|||
| InChIKey |
GHYOCDFICYLMRF-UTIIJYGPSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Immunoproteasome complex (IP) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04628936) An Open-label Extension to the Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis. U.S.National Institutes of Health. | |||
| REF 2 | Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses. Front Immunol. 2023 Mar 10;14:1043680. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.